Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Zimmer Biomet Holdings, Inc., West Pharmaceutical Services or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Latest Health Care Equipment & Supplies and Zimmer Biomet Holdings, Inc., West Pharmaceutical Services, Inc. Stock News

As of September 2, 2026, Zimmer Biomet Holdings, Inc. had a $19.0 billion market capitalization, compared to the Health Care Equipment & Supplies median of $416.1 million. Zimmer Biomet Holdings, Inc.’s stock is up 10% in 2026, down 0.6% in the previous five trading days and down 5.25% in the past year.

Currently, Zimmer Biomet Holdings, Inc.’s price-earnings ratio is 24.2. Zimmer Biomet Holdings, Inc.’s trailing 12-month revenue is $8.5 billion with a 9.5% net profit margin. Year-over-year quarterly sales growth most recently was 4.8%. Analysts expect adjusted earnings to reach $8.534 per share for the current fiscal year. Zimmer Biomet Holdings, Inc. currently has a 1.0% dividend yield.

As of September 2, 2026, West Pharmaceutical Services, Inc. had a $24.1 billion market cap, putting it in the 88th percentile of all stocks. West Pharmaceutical Services, Inc.’s stock is up 24.6% in 2026, down 1% in the previous five trading days and up 40.57% in the past year.

Currently, West Pharmaceutical Services, Inc.’s price-earnings ratio is 43.9. West Pharmaceutical Services, Inc.’s trailing 12-month revenue is $3.3 billion with a 17.0% net profit margin. Year-over-year quarterly sales growth most recently was 13.8%. Analysts expect adjusted earnings to reach $8.959 per share for the current fiscal year. West Pharmaceutical Services, Inc. currently has a 0.3% dividend yield.

How We Compare Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc. Stock Value Grades

Company	Ticker	Value
Zimmer Biomet Holdings, Inc.	ZBH	C
West Pharmaceutical Services, Inc.	WST	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Zimmer Biomet Holdings, Inc. has a Value Score of 55, which is Average. West Pharmaceutical Services, Inc. has a Value Score of 12, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Zimmer Biomet Holdings, Inc., West Pharmaceutical Services or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Zimmer Biomet Holdings, Inc., West Pharmaceutical Services or Inc. is the better investment when it comes to value.

Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc. Growth Grades

Company	Ticker	Growth
Zimmer Biomet Holdings, Inc.	ZBH	A
West Pharmaceutical Services, Inc.	WST	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Zimmer Biomet Holdings, Inc. has a Growth Score of 100, which is Very Strong. West Pharmaceutical Services, Inc. has a Growth Score of 95, which is Very Strong.

The Growth Grade Winner: It’s a Tie!

Looking at the Growth Grade breakdown above, both Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc. have a grade of A. For investors who focus solely on a company’s upward growth, further research should be conducted into both companies’ other financial metrics before deciding whether to invest.

Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc.’s Momentum Grades

Company	Ticker	Momentum
Zimmer Biomet Holdings, Inc.	ZBH	C
West Pharmaceutical Services, Inc.	WST	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Zimmer Biomet Holdings, Inc. has a Momentum Score of 47, which is Average. West Pharmaceutical Services, Inc. has a Momentum Score of 69, which is Strong.

The Momentum Grade Winner: West Pharmaceutical Services, Inc.

As you can clearly see from the Momentum Grade breakdown above, West Pharmaceutical Services, Inc. is considered to have stronger momentum compared to Zimmer Biomet Holdings, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, West Pharmaceutical Services, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc. Grades

In addition to Value, Growth and Momentum, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Zimmer Biomet Holdings, Inc., West Pharmaceutical Services or Inc. Stock?

Overall, Zimmer Biomet Holdings, Inc. stock has a Value Score of 55, Growth Score of 100 and Momentum Score of 47.

West Pharmaceutical Services, Inc. stock has a Value Score of 12, Growth Score of 95 and Momentum Score of 69.

Comparing Zimmer Biomet Holdings, Inc., West Pharmaceutical Services and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.